Financial Performance - The company achieved a revenue of RMB 11,812.34 million for the fiscal year ending December 31, 2024, with a net profit attributable to shareholders of RMB 2,061.10 million[12]. - The total revenue for the year was RMB 12.430 billion, with a net profit attributable to shareholders of RMB 2.061 billion[23]. - The company's operating revenue for 2024 was RMB 11,812,338.85 million, a decrease of 4.97% compared to 2023[56]. - Net profit attributable to shareholders increased by 5.50% to RMB 2,061,095.80 million in 2024[56]. - The basic earnings per share rose by 6.67% to RMB 2.24 in 2024[56]. - The net cash flow from operating activities decreased by 8.31% to RMB 2,978,847.53 million[56]. - Total assets decreased by 2.35% to RMB 24,455,825.70 million as of December 31, 2024[56]. - Total liabilities decreased by 7.08% to RMB 9,550,079.10 million[56]. - The return on equity for shareholders increased to 14.87%, up by 0.96 percentage points from 2023[56]. - The company reported a total of RMB 81,899,978.50 million in non-recurring gains and losses for 2024[60]. Research and Development - R&D investment accounted for 8.84% of total revenue, focusing on gastrointestinal, reproductive assistance, and mental health fields[16]. - The company has 45 products in the pipeline, including 23 innovative drugs and high-barrier complex formulations[16]. - AI technology has been integrated into the entire R&D process, enhancing efficiency in drug discovery and clinical research[18]. - The company plans to increase investment in innovative drug research and development, focusing on core therapeutic areas such as digestive, mental health, and reproductive assistance[21]. - The company reported a total R&D expenditure of approximately RMB 1.044 billion, accounting for about 8.84% of total revenue[75]. - The company is focusing on self-research and business development (BD) to drive innovation, particularly in gastrointestinal, reproductive, and neurological fields[75]. - The company has established a modular and flat R&D management system to improve efficiency in project management and resource allocation[75]. - The company has initiated Phase III clinical trials for a recombinant anti-IL-17A/F monoclonal antibody for psoriasis, aiming for market submission in 2025[78]. - The company is advancing multiple high-barrier complex formulations and high clinical value products, with several expected to be submitted for listing by 2025[82]. Market Expansion and Sales - The company reported a 65.98% year-on-year increase in overseas sales revenue for its formulation products[17]. - The export revenue of raw materials and intermediates reached RMB 1.668 billion, an increase of 7.93% year-on-year[19]. - The company achieved overseas revenue of RMB 1.724 billion, accounting for 14.59% of total revenue, with a year-on-year growth of 9.69%[92]. - The overseas sales revenue of formulation products grew by 65.98%, covering areas such as reproductive assistance and antiviral products[94]. - The company completed 202 international registration projects for APIs and intermediates in 94 countries/regions, obtaining 32 international certification certificates[93]. - The company has established branches in Malaysia and offices in Brazil, India, Spain, Vietnam, and Turkey to enhance its global commercialization strategy[103]. Compliance and Quality Management - The group achieved 100% compliance with GMP inspections for all production lines of listed products, with zero 483 records during FDA inspections[20]. - The company emphasizes compliance with the Chinese Accounting Standards and relevant regulations[35]. - The company has implemented strict compliance measures in its marketing activities, establishing a comprehensive risk monitoring mechanism[87]. - The company has established a comprehensive quality management system covering the entire product lifecycle, ensuring continuous improvement in production operations[89]. Corporate Governance and Sustainability - The company has been rated MSCI ESG AAA for two consecutive years and was recognized as the "Best Progress Company in the Industry" in the 2024 Sustainable Development Yearbook[21]. - The company integrates sustainable development goals into management performance assessments, promoting green production and social responsibility[96]. - The company has established a standardized public welfare management system focusing on rural revitalization, education support, medical assistance, and disaster response, contributing to local farmers' income through the "Huangqi Industry Revitalization" project[97]. Investment and Financial Strategy - The company approved a credit limit of RMB 26,455.00 million, with actual bank credit utilized amounting to RMB 4,678.36 million[148]. - The company has committed a total investment of RMB 142,030.04 million for various projects, with a cumulative investment of RMB 142,030.04 million achieved by the end of the reporting period[181]. - The company plans to use the raised funds for the deep development and industrialization of the Aiprazole series innovative products, construction of a long-acting microsphere technology R&D platform, and expansion projects[178]. - The company has established a foreign exchange risk management policy to hedge against currency fluctuations affecting its foreign currency assets[173]. - The company has implemented strict controls to prevent speculative trading in its derivative investments, adhering to a prudent and stable operational principle[173]. Employee and Organizational Development - The company has a research and development team of over 900 members, ensuring efficient project execution and rapid transformation of introduced research projects[100]. - The company has developed a digital training platform, "Lizhu Cloud Academy," providing over 100 hours of training per employee annually to support career development[98]. - The number of R&D personnel increased slightly by 0.22% to 908, with a notable increase in bachelor's degree holders by 7.13% to 556[130].

自12月4日以来公司已连续15日进行回购，合计回购298.83万股，累计回购金额8096.97万港元。 其间该 股累计上涨1.31%。 丽珠医药回购明细 证券时报•数据宝统计，丽珠医药在港交所公告显示，12月24日以每股26.850港元至27.200港元的价格回 购15.27万股，回购金额达413.97万港元。该股当日收盘价27.100港元，上涨0.93%，全天成交额1029.16 万港元。 今年以来该股累计进行86次回购，合计回购2589.78万股，累计回购金额8.42亿港元。（数据宝） ...

Financial Performance - Operating revenue for Q3 2024 was RMB 2,799,249,537.14, down 5.59% year-over-year, while year-to-date revenue was RMB 9,081,603,788.36, a decrease of 5.94%[2] - Net profit attributable to shareholders for Q3 2024 was RMB 501,763,106.12, an increase of 7.45% year-over-year, with year-to-date net profit at RMB 1,672,733,989.63, up 4.44%[2] - Basic earnings per share for Q3 2024 was RMB 0.54, reflecting an increase of 8.00% compared to the same period last year[2] - The company's operating revenue for the first nine months of 2024 was RMB 9,081.60 million, a decrease of 5.94% compared to RMB 9,654.79 million in the same period of 2023[6] - Operating profit increased to RMB 2,315,421,100.65, up 16.48% from RMB 1,987,239,809.53 year-on-year[17] - Net profit attributable to shareholders of the parent company reached RMB 1,672,733,989.63, representing a growth of 4.44% compared to RMB 1,601,554,878.96 in the previous year[17] - Total comprehensive income for the first nine months of 2024 was RMB 1,896,000,641.95, an increase from RMB 1,548,036,443.08 year-on-year[18] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 24,909,308,152.30, a decrease of 0.54% compared to the previous year-end[2] - The total current assets decreased from RMB 17,266,174,718.28 at the beginning of the year to RMB 16,613,394,001.59 at the end of the period[15] - The company's cash and cash equivalents decreased from RMB 11,325,723,855.76 to RMB 10,732,685,456.90[15] - The total non-current assets increased from RMB 7,778,652,409.47 to RMB 8,295,914,150.71[15] - Total liabilities decreased to RMB 9,973,518,408.08 from RMB 10,278,124,131.71, a reduction of 2.97%[16] - Current liabilities increased to RMB 9,013,265,318.62, up 11.43% from RMB 8,087,137,474.74 at the beginning of the year[16] - The company's total equity attributable to shareholders of the parent company rose to RMB 14,158,595,462.73, an increase from RMB 14,042,495,302.72[16] Cash Flow - The net cash flow from operating activities for the year-to-date period was RMB 2,307,915,362.28, reflecting a growth of 4.32%[2] - Operating cash inflow for the period (January to September 2024) was RMB 10,217,108,238.70, a decrease of 5.2% from RMB 10,775,261,897.57 in the same period of 2023[19] - Net cash flow from operating activities increased to RMB 2,307,915,362.28, up 4.3% from RMB 2,212,403,355.39 year-on-year[19] - Cash inflow from financing activities increased to RMB 3,166,957,767.39, up 14.3% from RMB 2,770,410,168.70 in the previous year[20] - Net cash flow from financing activities was negative at RMB -1,912,251,596.10, worsening from RMB -1,768,301,850.08 year-on-year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 41,320, with the top ten shareholders holding significant stakes[8] - The largest shareholder, Hong Kong Central Clearing Limited, held 33.11% of the shares, amounting to 306,768,789 shares[8] - As of September 30, 2024, the company repurchased a total of 7,855,000 A-shares, accounting for 0.85% of the total share capital, with a total expenditure of RMB 276,508,263.84[12] - The company repurchased 4,763,400 H-shares, with 2,778,800 shares canceled on June 28, 2024, representing 0.21% of the total share capital, and a total expenditure of HKD 116,981,345.00[13] Other Financial Metrics - Financial expenses decreased by 74.63% to RMB -54.93 million, primarily due to reduced interest income and foreign exchange fluctuations[6] - Investment income fell by 48.98% to RMB 25.90 million, mainly due to changes in the profits of associated companies[6] - Research and development expenses were RMB 734,493,897.75, down 25.49% from RMB 985,755,413.94 in the same period last year[17] - Other comprehensive income after tax showed an improvement, with a net amount of RMB -49,894,257.61 compared to RMB -76,284,738.91 in the previous year[18] - The fair value change income was RMB -5.50 million, an improvement of 86.90% compared to RMB -41.99 million in the previous year, mainly due to fluctuations in the market value of securities investments[6]

Financial Performance - The total revenue for the first half of 2024 was RMB 6,282.35 million, representing a decrease of 6.09% compared to the same period in 2023[17]. - The net profit attributable to shareholders was RMB 1,170.97 million, down 3.21% year-over-year[17]. - The cash flow from operating activities was RMB 1,155.47 million, reflecting a decrease of 5.65% compared to the previous year[17]. - The basic earnings per share increased to RMB 1.27, up 4.10% from RMB 1.22 in the same period last year[18]. - The overall revenue from raw materials and intermediates was RMB 745.01 million, reflecting a decrease of 11.86%[20]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2024, representing a 15% year-over-year growth[33]. - The company reported a revenue of RMB 6,282.35 million for the first half of 2024, a decrease of 6.09% compared to RMB 6,689.92 million in the same period last year[46]. - Net profit attributable to shareholders was RMB 1,170.97 million, reflecting a growth of 3.21% from RMB 1,134.57 million year-on-year[46]. - The net profit excluding non-recurring gains and losses was RMB 1,155.47 million, an increase of 5.65% from RMB 1,093.71 million in the previous year[47]. - The net cash flow from operating activities increased by 24.67% to RMB 1,530.03 million, compared to RMB 1,227.31 million in the previous period[40]. Revenue Breakdown - The revenue from chemical preparations accounted for 28.03% of total revenue, amounting to RMB 1,761.08 million[20]. - The revenue from biological products decreased by 61.23%, totaling RMB 70.52 million[21]. - The company’s revenue from traditional Chinese medicine preparations increased by 32.33%, reaching RMB 394.35 million[21]. - Sales revenue from chemical preparations was RMB 3,223.84 million, a decline of 7.37%, accounting for 51.32% of the total revenue[49]. - The sales revenue of the biopharmaceutical segment was RMB 87.55 million, a year-on-year decrease of 22.80%, accounting for 1.39% of the total revenue[55]. - The sales revenue of raw materials and intermediates segment reached RMB 1,761.08 million, a year-on-year decrease of 1.16%, accounting for 28.03% of the total revenue[58]. - The sales revenue of traditional Chinese medicine preparations was RMB 745.01 million, down 21.89% year-on-year, representing 11.86% of total revenue[62]. - The sales revenue of diagnostic reagents and equipment increased by 32.33% year-on-year to RMB 394.35 million, making up 6.28% of total revenue[64]. Future Outlook and Strategies - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 10% to 12%[33]. - New product development includes the launch of a novel drug expected to enter the market by Q4 2024, which is anticipated to generate an additional 300 million RMB in revenue[33]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[33]. - A strategic acquisition of a local pharmaceutical company is in progress, which is expected to enhance the company's production capacity by 30%[33]. - The company plans to enhance its digital marketing strategies, aiming for a 15% increase in online sales by the end of 2024[33]. - The company is focusing on core areas such as gastrointestinal, neuropsychiatric, reproductive assistance, metabolism, and anti-infection for its chemical preparations segment in the second half of 2024[53]. Research and Development - The company has invested 100 million RMB in R&D for innovative drug formulations in the first half of 2024, a 50% increase from the previous year[33]. - The company has made significant progress in key projects, including the approval of the 8 mg hydrochloride paliperidone tablets and the submission of supplementary materials for the injection of triptorelin microspheres for endometriosis[50]. - The company is advancing the development of key biopharmaceutical projects, including the completion of patient enrollment for the phase III clinical trial of recombinant human follicle-stimulating hormone injection[55]. - The company is actively expanding its international business, with the injection of acetic acid cyproterone approved for sale in the United States and ongoing sales and registration efforts in multiple countries[51]. - The company has established a modular and flat R&D management system, enhancing project management and resource allocation for competitive innovation projects[50]. - The company is focusing on evidence-based marketing and compliance marketing to promote its core products effectively[51]. Investment and Financial Management - The company has received emergency use approval for its bivalent COVID-19 vaccine, which has been shipped to multiple provinces for vaccination[56]. - The company aims to accelerate the commercialization process of its biopharmaceutical products while enhancing its quality management system[57]. - The company has a rolling bill pool business limit of RMB 1.8 billion, with a pledged balance of RMB 296,090,600[104]. - The company has received production approval for several new products, including the injection of aripiprazole microspheres for schizophrenia, which is expected to enhance its product offerings[81]. - The company has made significant equity investment of RMB 1,000,000,000 in Zhuhai Lizhu Biological, holding a 60.23% stake[133]. - The company reported a loss from the investment in Zhuhai Lizhu Biological of RMB -106,335,367.68[134]. - The company has established a management system for commodity futures hedging to mitigate market risks associated with commodity price fluctuations[142]. Share Repurchase and Capital Management - The company approved a share repurchase plan for A-shares with a total fund amount between RMB 400 million and RMB 600 million, with a maximum repurchase price of RMB 38.00 per A-share[199]. - As of June 30, 2024, the company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total issued share capital and 0.35% of the total issued A-shares, with a total expenditure of RMB 73,436,534.00[199]. - In July 2024, the company repurchased an additional 2,741,600 A-shares, representing 0.30% of the total issued share capital and 0.44% of the total issued A-shares, with a total expenditure of RMB 98,431,542.00[200]. - The repurchased A-shares have not yet been canceled and will reduce the registered capital upon cancellation[200]. - The company aims to stabilize its development and protect shareholder interests through this repurchase initiative[199].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 麗 珠 醫 藥 集 團 股 份 有 限 公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 截至2024年6月30日止六個月的未經審計中期業績公告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬公 司統稱為「本集團」）董事會（「董事會」）謹此宣佈本集團截至2024年6月30日止六個月的未 經審計中期業績。本業績公告列載本公司2024年中期報告全文，並符合《香港聯合交易所 有限公司證券上市規則》中有關中期業績初步公告附載的資料之要求。 本業績公告的中英文版本可在本公司網站(www.livzon.com.cn)和香港交易及結算所有限公 司（「香港交易所」）網站(www.hkexnews.hk)查閱。 2024年中期報告將於適當時候於香港交易所網站(w ...

Financial Performance - In 2023, Livzon Pharmaceutical Group achieved a revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[8] - The net profit attributable to shareholders was RMB 1,953.65 million, reflecting a year-on-year growth of 2.32%[8] - The company reported a total operating revenue of RMB 12,430.04 million, reflecting a decrease of 1.58% compared to the previous year[15] - The net profit attributable to shareholders was RMB 1,953.65 million, with a decrease of 2.32% year-on-year[15] - The company reported a significant decline of 79.33% in revenue from traditional Chinese medicine products, totaling RMB 84.43 million[19] - The company achieved a 17.18% increase in cash flow from operating activities, amounting to RMB 2,382.67 million[16] - The company reported a total cash flow from operating activities of RMB 1.04 billion in Q4 2023, showing a positive trend in cash generation[39] - The company’s net profit from core business, excluding non-recurring items, was RMB 1,881.35 million, a slight increase of 0.05% year-on-year[48] - The company reported a significant increase of 6,218.19% in current non-current liabilities, primarily due to the reclassification of long-term borrowings[100] Dividend Distribution - The company plans to distribute a cash dividend of RMB 13.50 per 10 shares, pending approval at the annual general meeting[8] - The dividend distribution is based on the total share capital as of the record date, excluding repurchased but not canceled shares[20] - The expected payment dates for the cash dividends are July 8, 2024, for A-share shareholders and August 5, 2024, for H-share shareholders[20] Research and Development - The company has made significant progress in its R&D innovation system, focusing on differentiated product pipelines in areas such as oncology and reproductive health[9] - The company plans to focus on enhancing R&D efficiency in innovative drugs and complex formulations, particularly in gastrointestinal, mental health, reproductive assistance, and oncology fields[13] - The company has initiated multiple clinical trials, including a Phase III trial for recombinant human IL-17A/F monoclonal antibody injection and completed enrollment for semaglutide injection for type 2 diabetes[10] - The company is focusing on R&D in high-barrier complex formulations and innovative drugs, particularly in reproductive health and oncology[41] - The company is actively pursuing non-equity investments, with a focus on securities investments valued at RMB 198,586,942.57[128] - The company is committed to increasing its R&D investment to improve innovation capabilities and adapt to industry policy changes[182] - The company emphasizes the importance of addressing unmet clinical needs and will continue to invest in innovative research and development of high-value innovative drugs and complex formulations[186] Product Development and Approvals - In 2023, 40 innovative drugs were approved for listing in China, maintaining a stable number of new drug approvals[7] - New products approved in 2023 include Triptorelin Acetate Microspheres and a new indication for Apremilast, enhancing the company's competitive position in various therapeutic areas[9] - The company received emergency use approval for a bivalent COVID-19 vaccine in December 2023, improving accessibility for patients[9] - The company has successfully launched several new products, including tocilizumab injection and new indications for injectable esomeprazole sodium, which are expected to enhance the product pipeline in their respective therapeutic areas[81] - The company is advancing multiple clinical research projects, including treatments for prostate cancer and gastrointestinal diseases, which are expected to enrich its product pipeline[88] Market Strategy and Expansion - The company aims to accelerate the internationalization of its products to ensure sustainable long-term development[9] - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2025[27] - The company has introduced innovative drugs in the gastrointestinal and cardiovascular fields, enhancing its international collaboration and licensing efforts[11] - The company is focusing on expanding its product offerings in the mental health sector with the development of Paliperidone injection for schizophrenia, currently in BE testing[85] - The company is exploring international markets and partnerships for innovative drug development to support its globalization strategy[186] Sustainability and ESG - The company’s MSCI ESG rating reached the highest level of AAA, making it the first Chinese pharmaceutical company to achieve this rating[12] - The company aims to achieve carbon neutrality by 2055, emphasizing its commitment to sustainable development and environmental responsibility[14] - The company is committed to strict compliance with environmental regulations, which may increase operational costs but is essential for sustainable practices[189] Financial Management and Investments - The company has invested 150 million RMB in new technology development, focusing on advanced manufacturing processes[27] - The company has completed 167 registration projects for raw materials and intermediates in 103 overseas countries/regions, with 27 international certification certificates obtained[56] - The company has reported a significant asset impairment of ¥310,038,083.02, accounting for -13.01% of total profit, primarily due to inventory write-downs[92] - The company has capital commitments totaling RMB 709.93 million as of December 31, 2023, significantly up from RMB 406.79 million at the end of 2022[116] - The company has made significant equity investments totaling RMB 702,000,000, with a projected loss of RMB -11,178,981.98 for the current period[126] Investor Relations - The company engaged in multiple investor communications throughout 2023, including discussions with institutions like 博裕资本 and IronBirch Capital regarding operational conditions and future development directions[191][192] - The company maintained transparency by not providing any written materials during these discussions, ensuring that all information shared was accurate and factual[191][192] - The company’s investor relations activities were consistently documented and made available on the 巨潮 website for public access[191][192] Operational Efficiency - The company is committed to enhancing its internal operations management and improving supply chain efficiency through smart manufacturing and automation[176] - The company has established a comprehensive quality management system, ensuring the safety and stability of its products[65] - The company is enhancing its quality management system and production processes, leading to improved operational capabilities and cost control[52]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 3,242,814,513.73, a decrease of 4.99% compared to CNY 3,413,055,191.98 in the same period last year[6] - Net profit attributable to shareholders for Q1 2024 was CNY 607,823,809.46, representing an increase of 4.45% from CNY 581,909,331.89 year-on-year[6] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.65, up 4.84% from CNY 0.62 in the same quarter last year[6] - The company reported a gross profit margin of approximately 64.7%, compared to 63.1% in the previous period, indicating an improvement in profitability[38] - The total comprehensive income for the current period is RMB 693,127,170.79, an increase from RMB 547,848,808.47 in the previous period[39] Cash Flow - The net cash flow from operating activities surged by 208.30% to CNY 924,248,920.31, compared to CNY 299,784,593.85 in the previous year[6] - Cash flow from operating activities increased by 208.30% to RMB 924.25 million, attributed to reduced procurement and expense outflows[22] - Operating cash flow for the current period is RMB 924,248,920.31, a significant increase from RMB 299,784,593.85 in the previous period, reflecting a growth of approximately 208.5%[41] - Total cash inflow from operating activities is RMB 3,508,763,815.99, compared to RMB 3,446,124,787.42 in the prior period, indicating a slight increase of about 1.8%[41] - The net increase in cash and cash equivalents for the current period is -RMB 188,391,565.87, compared to an increase of RMB 527,826,015.13 in the previous period[43] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 25,189,695,757.11, reflecting a slight increase of 0.58% from CNY 25,044,827,127.75 at the end of the previous year[8] - The total liabilities decreased to RMB 9,750,195,000.46 from RMB 10,278,124,131.71, reflecting a reduction of approximately 5.12%[37] - The company's total equity increased to RMB 15,439,500,756.65 from RMB 14,766,702,996.04, representing a growth of about 4.54%[37] - The company's cash and cash equivalents stood at RMB 11,143,148,609.60, down from RMB 11,325,723,855.76 at the beginning of the year[35] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,751, with 43,538 being A-share shareholders[25] - The largest shareholder, Hong Kong Central Clearing Limited, holds 33.41% of shares, totaling 309,547,589 shares[25] - The company has initiated a share buyback program, resulting in treasury shares amounting to CNY 128,431,667.85[17] - The company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total share capital, with a total expenditure of RMB 73,436,534.00[30] - The company also repurchased 2,476,300 H-shares, representing 0.27% of the total share capital, with a total expenditure of HKD 60,363,260.00[31] Investment and Income - Investment income decreased by 58.41% to RMB 15.72 million, primarily due to last year's dividend income[22] - The company reported a 238.80% increase in minority shareholders' profit to RMB 108.26 million, driven by improved performance of non-wholly owned subsidiaries[22] - Other comprehensive income improved by 65.23%, primarily due to changes in the fair value of other equity instruments and foreign exchange fluctuations[22] Research and Development - Research and development expenses for the current period were RMB 238,173,559.46, down 23.5% from RMB 311,408,248.52 in the previous period[38] Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 17,522,920.17, primarily driven by government subsidies and asset disposals[13] - Other receivables increased by 43.55% to CNY 45,948,492.93, mainly due to an increase in export tax refunds[17] - The company reported a significant increase of 203.07% in other current assets, totaling CNY 156,230,044.47, attributed to new cash management operations[17] - The company's short-term borrowings decreased to RMB 1,360,009,625.00 from RMB 1,860,009,625.00, a reduction of 27%[37] - The deferred income tax liabilities decreased to RMB 202,497,603.77 from RMB 209,812,292.82, a decline of about 3.5%[37] Audit Status - The company has not undergone an audit for the first quarter report[45]

Financial Performance - For the year 2023, the company achieved a revenue of RMB 12,430.04 million, a year-on-year decrease of 1.58%[16] - The net profit attributable to shareholders for 2023 was RMB 1,953.65 million, representing a year-on-year increase of 2.32%[16] - Excluding non-recurring gains and losses, the net profit from core business for 2023 was RMB 1,881.35 million, a slight increase of 0.05% year-on-year[16] - The company reported total operating revenue of RMB 12,430.04 million, representing a year-on-year increase of 2.94%[28] - The net profit attributable to shareholders was RMB 1,744.89 million, reflecting a growth of 14.04% compared to the previous year[29] - The company reported a net profit of RMB 581,909,331.89 thousand in the first quarter of 2023[65] - The company reported a total operating cost of RMB 4,465,473,361.10, a slight increase of 0.09% from RMB 4,461,283,076.09 in 2022[118] - The income tax expense for the year was RMB 485.07 million, an increase of 29.36% year-on-year, primarily due to the company's operating results[129] - The company has made adjustments to previous years' financial data due to changes in accounting policies[58] Dividend and Shareholder Returns - The board proposed a cash dividend of RMB 13.50 per 10 shares (before tax) for the 2023 fiscal year, pending approval at the annual general meeting[17] - The company plans to distribute a cash dividend of RMB 13.50 per 10 shares to all shareholders, pending approval at the 2023 annual general meeting[37] - The dividend distribution is expected to occur on July 8, 2024, for A-share shareholders and August 5, 2024, for H-share shareholders[37] Research and Development - In 2023, the company focused on R&D innovation, particularly in the fields of digestive, mental health, reproductive assistance, and oncology, enhancing its differentiated product pipeline[18] - The company has established a robust R&D innovation system, optimizing management structures across clinical operations and drug safety, leading to accelerated realization of innovative research outcomes[18] - The company aims to enhance R&D efficiency and strengthen its leading position in innovative drugs and complex formulations, focusing on areas such as digestive, mental health, reproductive assistance, and oncology[24] - The company has initiated multiple clinical trials, including a Phase III trial for recombinant human IL-17A/F monoclonal antibody injection and completed enrollment for semaglutide injection for type 2 diabetes[20] - The company has made significant progress in R&D, with the approval of the injection of Triptorelin Acetate microspheres for prostate cancer and the completion of Phase III clinical trials for endometriosis[78] - The company is advancing several R&D projects, including a long-acting implant for prostate cancer and a micro-injection for endometriosis, all in preclinical research stages[137] Market Expansion and Product Development - The company accelerated the internationalization of its products, contributing to a comprehensive enhancement of its long-term sustainable development capabilities[14] - The company introduced innovative drugs in the gastrointestinal and cardiovascular fields, strengthening its international collaboration and licensing efforts[21] - The company has analyzed potential risk factors and response strategies for future development in the management discussion and analysis section of the report[37] - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales from this region by 2025[45] - The company is actively pursuing international collaboration and innovation business models to enhance its global market presence[69] - The company is focusing on high-barrier complex formulations and innovative drugs, strengthening its integrated raw material and formulation capabilities[98] Environmental and Social Responsibility - The company achieved an MSCI ESG rating of AAA, becoming the first Chinese pharmaceutical company to receive this highest rating[23] - The company plans to achieve carbon neutrality by 2055 and is committed to increasing environmental protection investments[26] Financial Position and Assets - The total assets as of December 31, 2023, were RMB 25,044,827.13 thousand, reflecting a 0.71% increase from the previous year[59] - The total liabilities increased by 3.49% to RMB 10,278,124.13 thousand as of December 31, 2023[59] - The return on equity attributable to shareholders was 13.91%, an increase of 0.15 percentage points compared to the previous year[59] - The company's asset-liability ratio increased from 39.94% in 2022 to 41.04% in 2023[157] - The total outstanding debt as of December 31, 2023, is RMB 5,014.84 million, an increase from RMB 4,604.43 million as of December 31, 2022, representing an increase of 8.9%[171] Risk Management and Compliance - The company has implemented long-term equity incentive plans to motivate employees and align their growth with the company's development[23] - The company continues to address corruption issues in the pharmaceutical industry through a comprehensive governance approach initiated by the National Health Commission[3] - Forward-looking statements in the report are subject to risks and uncertainties, and actual results may differ significantly from these statements[37] Investment and Financing Activities - The company has made significant equity investments, including RMB 600 million in Wuhan Kangli Health Investment, acquiring a 60% stake, and RMB 102 million in Guangdong Lijian Animal Health, acquiring a 51% stake[183] - The total investment amount for the year reached RMB 729.64 million, a significant increase of 1,724.08% compared to RMB 40.00 million in the previous year[182] - The company has capital commitments totaling RMB 709.93 million, which includes commitments for long-term asset construction and R&D expenditures[168] Product Pipeline and Approvals - The company has successfully launched several new products, including tocilizumab injection and new indications for injectable esomeprazole sodium, enhancing its product pipeline in various therapeutic areas[131] - The company has received emergency use authorization for the recombinant novel coronavirus fusion protein vaccine, which is expected to enrich its vaccine product pipeline[133] - The injectable progesterone solution for women undergoing assisted reproductive technology has been submitted for approval, aiming to expand the company's offerings in the reproductive health sector[133] - The injectable phosphoric acid tedizolid for acute bacterial skin and skin structure infections has been submitted for market approval, which will enhance the company's infection control product pipeline[133]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 麗 珠醫 藥集 團股 份有 限公 司 LIVZON PHARMACEUTICAL GROUP INC.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：1513） 2023年第三季度報告 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「公司」或「本公司」，連同其 附屬公司，統稱「本集團」）根據香港聯合交易所有限公司證券上市規則第13.09條和第13.10B 條以及香港法例第571章證券及期貨條例第XIVA部內幕消息條文刊發本公告。 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記載、誤導性陳 述或重大遺漏。 重要內容提示： 1. 本公司董事會、監事會及董事、監事、高級管理人員保證公司2023年第三季度報告（「本 季度報告」）的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔 ...

Financial Performance - Livzon Pharmaceutical reported a revenue of RMB 6,689.92 million for the first half of 2023, representing a 6.15% increase compared to the same period in 2022[15]. - The net profit attributable to shareholders was RMB 1,227.31 million, reflecting a decrease of 13.96% year-over-year[15]. - The basic earnings per share increased by 11.93% to RMB 1.22 compared to RMB 1.09 in the previous year[16]. - Livzon Pharmaceutical's cash flow from operating activities was RMB 1,423.37 million, showing a 6.15% increase from the previous year[15]. - The company achieved operating revenue of RMB 6,689.92 million, a year-on-year increase of 6.15% compared to RMB 6,302.57 million in the same period last year[43]. - Net profit attributable to shareholders reached RMB 1,134.57 million, reflecting an 11.50% increase from RMB 1,017.55 million in the previous year[43]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 1,093.71 million, up 4.52% from RMB 1,046.42 million in the same period last year[43]. - The company reported a total income tax expense of RMB 249.30 million, which is a 21.57% increase year-on-year, primarily due to higher taxable income[76]. Revenue Breakdown - Revenue from chemical preparations reached RMB 3,480.29 million, accounting for 52.02% of total revenue[16]. - The revenue from biological products increased by 14.26% to RMB 953.85 million[16]. - The revenue from traditional Chinese medicine preparations reached RMB 953.85 million, a year-on-year increase of 94.42%, accounting for 14.26% of the total revenue[57]. - The revenue from diagnostic reagents and equipment was RMB 297.99 million, a year-on-year decrease of 13.88%, representing 4.45% of the total revenue[58]. - The revenue from APIs and intermediates was RMB 1,781.67 million, a year-on-year increase of 3.03%, accounting for 26.63% of the total revenue[54]. - The revenue from chemical agents was RMB 3,480.29 million, a year-on-year decrease of 2.42%, accounting for 52.02% of the total revenue[45]. - The revenue from biological products was RMB 113.41 million, a year-on-year increase of 5.93%, accounting for 1.70% of the total revenue[51]. Strategic Initiatives - The company is focusing on new product development and market expansion strategies to enhance growth prospects[18]. - Livzon plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2024[30]. - The company is investing RMB 200 million in R&D for new drug development, focusing on innovative therapies for chronic diseases[30]. - Livzon is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[30]. - The company is actively pursuing international cooperation and licensing for its innovative products and pipelines, with ongoing discussions with multiple international partners[60]. - The company has achieved a strategic partnership with leading global pharmaceutical companies, enhancing its market position[54]. Research and Development - The company has made significant progress in the development of new drugs, including the approval of the injection of leuprolide acetate microspheres for prostate cancer[46]. - The company has registered 20 products in 11 overseas countries/regions as of the end of the reporting period[49]. - The company has completed 135 international registration projects for APIs and intermediates in 63 overseas countries/regions[55]. - The company has nine ongoing research projects in traditional Chinese medicine, with the SXSHL gel completing preclinical studies and the TGDX granules finishing clinical trials[57]. - The company has 7 ongoing research projects for complex formulations, with 1 approved for market and 1 completing Phase III clinical trials[79]. - A total of 27 key projects are under research, with 3 approved for market and 4 in the production application stage[80]. - In the biopharmaceutical sector, there are 8 ongoing projects, with 2 approved for market and 1 approved for emergency use[81]. Market Expansion and Sales - User data indicates a growth in customer base by 25%, with over 5 million active users engaging with the company's products[30]. - The company expects a revenue guidance of RMB 2.5 billion for the full year 2023, reflecting a growth rate of 18%[30]. - The company plans to strengthen its marketing efforts in traditional Chinese medicine, focusing on the sales of specific products like the Qishi Fuzheng injection in oncology and expanding into pediatric and geriatric medicine[182]. - The company aims to improve its supply chain efficiency and strengthen quality management to prevent major quality safety incidents[177]. - The company will continue to focus on the research, production, and sales of pharmaceutical products, including various formulations and active pharmaceutical ingredients[42]. Financial Position and Liabilities - The total assets increased by 3.46% to RMB 25,726.13 million from RMB 24,864.83 million at the beginning of the period[42]. - Total liabilities rose by 15.59% to RMB 11,476.30 million from RMB 9,928.57 million at the beginning of the period[42]. - The asset-liability ratio rose from 39.93% to 44.61% as of June 30, 2023, indicating a higher level of debt relative to assets[94]. - The company's long-term borrowings rose by 32.81% to RMB 2,622,263,438.94, primarily due to new bank loans[92]. - The group’s total borrowings amounted to RMB 4,232.26 million as of June 30, 2023, up from RMB 3,596.68 million as of December 31, 2022, representing 16.45% of total assets[105]. Investment and Capital Expenditure - The company has invested RMB 54,850.66 million in the Sichuan Guangda relocation and expansion project, with government subsidies totaling RMB 17,443.17 million received[120]. - The company plans to invest a total of RMB 20,820.90 million in the new product development and industrial upgrading project, with expected annual investments over the next five years[145]. - The company has committed to using the raised funds for specific projects, including the development of innovative products and technology upgrades, aligning with its strategic goals[141]. - The company has reported a significant increase in investment amounting to RMB 727,085,150.00 for the current period, compared to RMB 30,000,065.77 in the previous period, reflecting a change of 2,323.61%[123]. - The company has allocated RMB 51,685.32 million for replenishing working capital and repaying bank loans, achieving 100% of the planned investment[154]. Risk Management and Compliance - The company has implemented a foreign exchange risk management system to mitigate the impact of currency fluctuations on its business[112]. - The company is actively monitoring industry policy changes and will strengthen its compliance and operational capabilities in response to evolving regulations[185]. - The company has established risk management measures to mitigate market, operational, and legal risks associated with derivative investments[136]. - The company aims to enhance its operational efficiency through improved risk management practices in derivative trading[136]. Sustainability and Environmental Initiatives - The company aims to achieve carbon neutrality by 2055, enhancing its commitment to green and low-carbon operations[195]. - The company has established GAP production bases for key traditional Chinese medicine raw materials to mitigate supply risks[194]. - The company aims to establish a green ecological planting base for key medicinal materials to support its core product research and development[182].